2014 Archived Content
Within the biopharmaceutical industry there is a growing emphasis on alliances and collaboration with external organizations driven by the need to access innovation, fill product pipelines, develop companion diagnostics, and ultimately, harness an alliance ecosystem to gain market access. Yet, despite the impetus to forge strategic partnerships, stakeholders are often confronted with the increasing complexities of systematically and effectively managing partnerships throughout their life cycles. Why do some alliances fail, while others bear fruit? How do partnering companies create a shared culture, develop trust, and maximize their investments? How does the alliance management function itself act as a central driver of value, while alleviating perturbations, and meeting alliance goals? Critical to the success of any strategic partnership is the ever evolving discipline of alliance management.
Cambridge Healthtech Institute’s 11th Annual Strategic Alliance Management Congress, brought together senior alliance management, business development, technology transfer and licensing professionals, to network, share experiences, discuss case studies, and to identify the components that cultivate successful partnerships. Delegates gained strategic insights, proven tools, methods, and perspectives from a variety of leaders advancing the art of alliance management.
KEYNOTE PRESENTATIONS:
Alliance Evolution: From Just Signing a License to
Getting Beyond the Deal
Frank Grams, Ph.D., Vice President, Head, Alliance
Management & Transactions, Sanofi
AbbVie, a New Type of Company; a New Model for
Alliance Management
Anna Maroney, Ph.D., Vice President, Head, Alliance
Management, AbbVie
Building an Alliance Management Culture and
Capabilities within Your Company - It Goes a Long Way
to Foster Healthy Collaborations and to Be a
Preferred Partner
Knut Sturmhoefel, Ph.D., Head, Alliance Management,
Global Business Development & Licensing, Novartis
CONFERENCE SESSIONS:
-
An AM Update: Insights into BioPharma Alliances
- From the Ground Up: Building and Continuously Improving (True) Alliance Capability
- Tackling Partnership Complexities: Managing and Expanding a Diverse Portfolio
- AM Insights: Initial Activities Impacting Alliance Success
- AM in Action
- Moving Toward Partner of Choice: Strategies for Standing Out
- Strategic Partnerships: Reinventing the Drug Development Paradigm
- Refining Service-Based and Diagnostic Partnerships
TOP 5 REASONS TO ATTEND:
- Connect with 100+ colleagues during dedicated networking sessions
- Listen to 20+ expert-led presentations and interactive panels
- Discuss challenges in AM during informal roundtables
- Gain in-depth training from tactical conference workshops
- Learn from real-world case studies
and co-presentations
FEATURING AM LEADERS FROM:
- AbbVie
- AstraZeneca
- Bayer Health Care Pharmaceuticals
- Blood Centers of America
- Bristol-Myers Squibb
- Celgene Corporation
- Cook General Biotechnologies
- Eli Lilly and Company
- Epizyme
- FDA
- HIKMA Pharmaceuticals
- IBM
- Incyte Corporation
- Institut de Recherches Internationales Servier
- LabCRO, Inc.
- Lana Management & Business Research International
- Merck
|
- Myraqa, Inc.
- Novartis Oncology
- Novartis
- Partners HealthCare
- Reata Pharmaceuticals
- Regenerex
- Sanofi
- Schrödinger
- Selventa
- Servier Monde
- SRI International
- Terumo BCT
- The Leukemia & Lymphoma Soc (LLS)
- University of California, San Diego
- University of Pennsylvania
- Vantage Partners
|
Day 1 | Day 2 | Day 3 | Short Courses